—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Bachem Holding AG (BANB.SW) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for BANB.SW, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against BANB.SW on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Bachem Holding AG

BANB.SW in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Bachem makes peptide-based active ingredients for drugmakers, covering both new peptide compounds and generic versions once patents expire. It also runs quality, regulatory and manufacturing services that let clients outsource production rather than build their own plants. The company is based in Bubendorf, Switzerland, and is majority owned by Ingro Finanz AG.
Where it sits in the stack
Bachem carries no seat in Rubin or Halo, our indices for the AI build-out and healthcare-innovation themes; it sits in the diary's broader Healthcare sector coverage as a peptide-manufacturing name rather than a stack constituent.
Who it is priced against
The diary's peer group draws on other scored Healthcare names, including argenx, Eli Lilly, Medpace, BeiGene and UCB; the market also names Novo Nordisk as a peptide-manufacturing comparison.
Why Closelooknet tracks it
Bachem carries a Closelooknet score with momentum as its strongest module and quality as its weakest; it holds no index seat and has drawn no diary quotes or mentions so far.
What the diary watches
Whether demand for peptide active ingredients, including generic versions as patents lapse, shifts the growth and quality readings that currently trail the rest of its score.

Bachem Holding AG (BANB.SW) trades on the SW exchange in Switzerland.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 0.54%, annual · last 0.43 CHF on 2026-05-04

Dividends and capital return

What BANB.SW pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.43 CHF per share · a 0.54% yield on the 2026-10-06 close 1 distribution, paid once a year 2026-10-06
  • Change on the year +2.6% against the prior twelve months prior twelve months 0.42 CHF per share
  • Last distribution 0.43 CHF per share as the price series records it, within days of the ex-date 2026-05-04
  • By calendar year 2025: 0.42 CHF (partial) · 2026: 0.43 CHF to date first distribution recorded in the three-year window: 2025-05-05

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Bachem Holding AG (BANB.SW)?

Bachem Holding AG trades as BANB.SW on the SW exchange (Switzerland) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is BANB.SW in a Closelooknet index?

Not currently — Bachem Holding AG is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does BANB.SW trade against its moving averages?

Uptrend stack intact: Trades +3.7% vs the 50-day and +14.4% vs the 200-day average, 4.7% below the 52-week high and +66.2% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Bachem Holding AG compare with its peers?

Against its peer group (Biotechnology), Bachem Holding AG (BANB.SW) sits 4.7% below its 52-week high, 3.7% above its 50-day average; BB Biotech AG (BION.SW) is 12.9% below, BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below. Put any of them next to BANB.SW in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Bachem Holding AG do?

Bachem makes peptide-based active ingredients for drugmakers, covering both new peptide compounds and generic versions once patents expire. It also runs quality, regulatory and manufacturing services that let clients outsource production rather than build their own plants. The company is based in Bubendorf, Switzerland, and is majority owned by Ingro Finanz AG. The diary's peer group draws on other scored Healthcare names, including argenx, Eli Lilly, Medpace, BeiGene and UCB; the market also names Novo Nordisk as a peptide-manufacturing comparison.

Where does Bachem Holding AG sit in the AI build-out?

Bachem carries no seat in Rubin or Halo, our indices for the AI build-out and healthcare-innovation themes; it sits in the diary's broader Healthcare sector coverage as a peptide-manufacturing name rather than a stack constituent. Bachem carries a Closelooknet score with momentum as its strongest module and quality as its weakest; it holds no index seat and has drawn no diary quotes or mentions so far.

Does Bachem Holding AG pay a dividend?

Bachem Holding AG has paid 0.43 CHF per share over the last twelve months, paid once a year, a trailing yield of 0.54% on the 2026-10-06 close; the last distribution recorded in the price series was 0.43 CHF on 2026-05-04. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for BANB.SW, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.